197 related articles for article (PubMed ID: 36438917)
1. Expression and function of Siglec-15 in RLPS and its correlation with PD-L1: Bioinformatics Analysis and Clinicopathological Evidence.
Cui L; Tian X; Yan L; Guan X; Dong B; Zhao M; Lv A; Liu D; Wu J; Hao C
Int J Med Sci; 2022; 19(13):1977-1988. PubMed ID: 36438917
[No Abstract] [Full Text] [Related]
2. Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma.
Yan L; Wang Z; Cui C; Guan X; Dong B; Zhao M; Wu J; Tian X; Hao C
Cancer Sci; 2019 Oct; 110(10):3038-3048. PubMed ID: 31385405
[TBL] [Abstract][Full Text] [Related]
3. Identification of TYMS as a promoting factor of retroperitoneal liposarcoma progression: Bioinformatics analysis and biological evidence.
Zhang S; Yan L; Cui C; Wang Z; Wu J; Zhao M; Dong B; Guan X; Tian X; Hao C
Oncol Rep; 2020 Aug; 44(2):565-576. PubMed ID: 32627015
[TBL] [Abstract][Full Text] [Related]
4. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
5. Significance of Siglec-15 expression in colorectal cancer: association with advanced disease stage and fewer tumor-infiltrating lymphocytes.
Lu Z; Cheng P; Huang F; Li J; Wang B; Zou S; Zheng Z; Peng C
J Pathol Clin Res; 2023 Mar; 9(2):121-128. PubMed ID: 36424637
[TBL] [Abstract][Full Text] [Related]
6. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of PD-L1 and Siglec-15 expression in patients with nasopharyngeal carcinoma.
Zhao J; Yang H; Hu H; Liu C; Wei M; Zhao Y; Chen Y; Cui Y; Chen P; Xiong K; Lu Y; Yang H; Yang L
Sci Rep; 2022 Jun; 12(1):10401. PubMed ID: 35729260
[TBL] [Abstract][Full Text] [Related]
8. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
[TBL] [Abstract][Full Text] [Related]
9. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma.
Huang Z; Guo Y; Li B; Shen M; Yi Y; Li L; Zhao X; Yang L
Cancer Gene Ther; 2024 Mar; 31(3):427-438. PubMed ID: 38072971
[TBL] [Abstract][Full Text] [Related]
10. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
[TBL] [Abstract][Full Text] [Related]
11. Tsp2 Facilitates Tumor-associated Fibroblasts Formation and Promotes Tumor Progression in Retroperitoneal Liposarcoma.
Xu C; Yan L; Guan X; Wang Z; Wu J; Lv A; Liu D; Liu F; Dong B; Zhao M; Jia L; Tian X; Hao C
Int J Biol Sci; 2022; 18(13):5038-5055. PubMed ID: 35982904
[TBL] [Abstract][Full Text] [Related]
12. Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma.
Que Y; Zhang XL; Liu ZX; Zhao JJ; Pan QZ; Wen XZ; Xiao W; Xu BS; Hong DC; Guo TH; Shen LJ; Fan WJ; Chen HY; Weng DS; Xu HR; Zhou PH; Zhang YZ; Niu XH; Zhang X
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637599
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.
Zheng C; You W; Wan P; Jiang X; Chen J; Zheng Y; Li W; Tan J; Zhang S
Medicine (Baltimore); 2018 Jun; 97(25):e11004. PubMed ID: 29923984
[TBL] [Abstract][Full Text] [Related]
14. PD-1 and PD-L1 expression in bone and soft tissue sarcomas.
Torabi A; Amaya CN; Wians FH; Bryan BA
Pathology; 2017 Aug; 49(5):506-513. PubMed ID: 28688724
[TBL] [Abstract][Full Text] [Related]
15. Siglec Signaling in the Tumor Microenvironment.
van Houtum EJH; Büll C; Cornelissen LAM; Adema GJ
Front Immunol; 2021; 12():790317. PubMed ID: 34966391
[TBL] [Abstract][Full Text] [Related]
16. Core needle biopsies alter the amounts of CCR5, Siglec-15, and PD-L1 positivities in breast carcinoma.
Mutka M; Joensuu K; Heiskala M; Eray M; Heikkilä P
Virchows Arch; 2023 Aug; 483(2):215-224. PubMed ID: 37222841
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Prognostic Implications of PD-L1 Expression in Soft Tissue Sarcomas.
Kelany M; Barth TF; Salem D; Shakweer MM
Pathol Oncol Res; 2021; 27():1609804. PubMed ID: 34276259
[No Abstract] [Full Text] [Related]
18. Identification of therapeutic targets and prognostic biomarkers in the Siglec family of genes in tumor immune microenvironment of sarcoma.
Qi L; Jiang K; Zhao FF; Ren P; Wang L
Sci Rep; 2024 Jan; 14(1):577. PubMed ID: 38182638
[TBL] [Abstract][Full Text] [Related]
19. Development of an immunohistochemical assay for Siglec-15.
Shafi S; Aung TN; Robbins C; Zugazagoitia J; Vathiotis I; Gavrielatou N; Yaghoobi V; Fernandez A; Niu S; Liu LN; Cusumano ZT; Leelatian N; Cole K; Wang H; Homer R; Herbst RS; Langermann S; Rimm DL
Lab Invest; 2022 Jul; 102(7):771-778. PubMed ID: 35459795
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 correlated gene expression profiles and tumor infiltrating lymphocytes in pancreatic cancer.
Li J; Yin L; Chen Y; An S; Xiong Y; Huang G; Liu J
Int J Med Sci; 2021; 18(14):3150-3157. PubMed ID: 34400885
[No Abstract] [Full Text] [Related]
[Next] [New Search]
